Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies

被引:4
|
作者
Mieczkowski, Carl [1 ]
Bahmanjah, Soheila [2 ]
Yu, Yao [1 ]
Baker, Jeanne [1 ]
Raghunathan, Gopalan [1 ]
Tomazela, Daniela [1 ]
Hsieh, Mark [1 ]
McCoy, Mark [3 ]
Strickland, Corey [2 ]
Fayadat-Dilman, Laurence [1 ]
机构
[1] Merck & Co Inc, Prot Sci, Discovery Biol, San Francisco, CA 94080 USA
[2] Merck & Co Inc, Dept Chem Modeling & Informat, Kenilworth, NJ 07033 USA
[3] Merck & Co Inc, Dept Pharmacol Mass Spectrometry & Biophys, Kenilworth, NJ 07033 USA
关键词
antibody; heavy-chain dimer; heavy-chain antibody; crystal structure; STRUCTURE REFINEMENT; ONLY ANTIBODIES; SECRETION; MODEL; HETEROGENEITY; CYSTEINES; PROTEIN;
D O I
10.3390/antib9040066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We report the novel crystal structure and characterization of symmetrical, homodimeric humanized heavy-chain-only antibodies or dimers (HC2s). HC2s were found to be significantly coexpressed and secreted along with mAbs from transient CHO HC/LC cotransfection, resulting in an unacceptable mAb developability attribute. Expression of full-length HC2s in the absence of LC followed by purification resulted in HC2s with high purity and thermal stability similar to conventional mAbs. The V-H and C(H)1 portion of the heavy chain (or Fd) was also efficiently expressed and yielded a stable, covalent, and reducible dimer (Fd2). Mutagenesis of all heavy chain cysteines involved in disulfide bond formation revealed that Fd2 intermolecular disulfide formation was similar to Fabs and elucidated requirements for Fd2 folding and expression. For one HC2, we solved the crystal structure of the Fd2 domain to 2.9 angstrom, revealing a highly symmetrical homodimer that is structurally similar to Fabs and is mediated by conserved (C(H)1) and variable (V-H) contacts with all CDRs positioned outward for target binding. Interfacial dimer contacts revealed by the crystal structure were mutated for two HC2s and were found to dramatically affect HC2 formation while maintaining mAb bioactivity, offering a potential means to modulate novel HC2 formation through engineering. These findings indicate that human heavy-chain dimers can be secreted efficiently in the absence of light chains, may show good physicochemical properties and stability, are structurally similar to Fabs, offer insights into their mechanism of formation, and may be amenable as a novel therapeutic modality.
引用
收藏
页码:1 / 24
页数:24
相关论文
共 39 条
  • [1] Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin
    Cheng, Kexuan
    Lu, Jiansheng
    Guo, Jiazheng
    Wang, Rong
    Chen, Lei
    Wang, Xi
    Jiang, Yujia
    Li, Yating
    Xu, Changyan
    Kang, Qinglin
    Qiaerxie, Gulisaina
    Du, Peng
    Gao, Chen
    Yu, Yunzhou
    Yang, Zhixin
    Wang, Wei
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [2] The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation
    B. P. Woolven
    Leon G. J. Frenken
    Paul van der Logt
    Peter J. Nicholls
    Immunogenetics, 1999, 50 : 98 - 101
  • [3] The structure of the Ilama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation
    Woolven, BP
    Frenken, LGJ
    van der Logt, P
    Nicholls, PJ
    IMMUNOGENETICS, 1999, 50 (1-2) : 98 - 101
  • [4] Generation and Characterization of Novel Human IRAS Monoclonal Antibodies
    Wang, Bo
    Liu, Ying
    Shan, Yajun
    Yao, Zhenyu
    Liu, Xiaolan
    Su, Ruibin
    Sun, Qihong
    Cong, Yuwen
    Li, Jin
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2009,
  • [5] Antagonist properties of monoclonal antibodies targeting human CD28 Role of valency and the heavy-chain constant domain
    Mary, Caroline
    Coulon, Flora
    Poirier, Nicolas
    Dilek, Nahzli
    Martinet, Bernard
    Blancho, Gilles
    Vanhove, Bernard
    MABS, 2013, 5 (01) : 47 - 55
  • [6] Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies
    Jiang, Guoying
    Yu, Christopher
    Yadav, Daniela B.
    Hu, Zhilan
    Amurao, Annamarie
    Duenas, Eileen
    Wong, Marc
    Iverson, Mark
    Zheng, Kai
    Lam, Xanthe
    Chen, Jia
    Vega, Roxanne
    Ulufatu, Sheila
    Leddy, Cecilia
    Davis, Helen
    Shen, Amy
    Wong, Pin Y.
    Harris, Reed
    Wang, Y. John
    Li, Dongwei
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (07) : 2066 - 2072
  • [7] The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin
    Rahbarizadeh, F
    Rasaee, MJ
    Forouzandeh, M
    Allameh, A
    Sarrami, R
    Nasiry, H
    Sadeghizadeh, M
    IMMUNOLOGICAL INVESTIGATIONS, 2005, 34 (04) : 431 - 452
  • [8] Role of NMR in High Ordered Structure Characterization of Monoclonal Antibodies
    Tokunaga, Yuji
    Takeuchi, Koh
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (01) : 1 - 12
  • [9] Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies
    Altintas, Isil
    Kok, Robbert Jan
    Schiffelers, Raymond M.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 45 (04) : 399 - 407
  • [10] Advancing secondary structure characterization of monoclonal antibodies using Microfluidic Modulation Spectroscopy
    Ivancic, Valerie A.
    Lombardo, Holly L.
    Ma, Eugene
    Wikstrom, Mats
    Batabyal, Dipanwita
    ANALYTICAL BIOCHEMISTRY, 2022, 646